Drug Profile


Alternative Names: BMS-512148; Farxiga; Forxiga; Oxra

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bristol-Myers Squibb; Ono Pharmaceutical; Uppsala University
  • Class Antihyperglycaemics; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Chronic heart failure; Renal failure; Type 1 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 23 Nov 2016 NICE recommends use of Dapagliflozin as triple therapy for Type 2 diabetes mellitus (in combination with metformin and a sulfonylurea) in the UK
  • 12 Sep 2016 Phase-III clinical trials in Chronic heart failure in United Kingdom (unspecified route)
  • 12 Sep 2016 Phase-III clinical trials in Renal failure in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top